Our weight loss program can help regulate your blood sugar levels and reduce your appetite, making it a great option for people with diabetes, pre-diabetes, or a high BMI
Jastreboff AM et al., NEJM 2022
GLP-1 Receptor Agonists Obesity Drugs Market Share The GLP-1 receptor agonists obesity drugs industry is primarily led by well-established companies, including: Novo Nordisk A/S (Denmark) Lilly (U.S.) Pfizer Inc
Contrave may be beneficial for individuals struggling with cravings and emotional eating triggered by anxiety and stress factors whereas Wegovys ability to induce prolonged feelings of fullness could result in sustainable weight loss outcomes in the long run
A total of 1,197 patients were randomized in a 2:1 ratio to receive semaglutide 2.4 mg subcutaneously once weekly or placebo for 240 weeks
GLP-1 agonists include (not all are available in Australia): semaglutide (brand names Ozempic, Wegovy, Rybelsus), liraglutide (Saxenda, Victoza), dulaglutide (Trulicity), exenatide (Byetta, Bydureon) and lixisenatide (Lyxumia, Adlyxin)
